Agenus Inc. (AGEN)
NASDAQ: AGEN · Real-Time Price · USD
6.22
-0.61 (-8.93%)
Jul 15, 2025, 4:00 PM - Market closed
Agenus Employees
Agenus had 316 employees as of December 31, 2024. The number of employees decreased by 73 or -18.77% compared to the previous year.
Employees
316
Change (1Y)
-73
Growth (1Y)
-18.77%
Revenue / Employee
$314,949
Profits / Employee
-$603,820
Market Cap
170.53M
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AGEN News
- 8 days ago - Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3 - Business Wire
- 4 weeks ago - Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology - Business Wire
- 5 weeks ago - Agenus Announces Virtual Annual Shareholders Meeting - Business Wire
- 5 weeks ago - Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang - Benzinga
- 6 weeks ago - Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the US - Business Wire
- 6 weeks ago - Agenus Presents New Data at ASCO Highlighting Botensilimab's Immune Activation in MSS Colorectal Cancer - Business Wire
- 7 weeks ago - Agenus: Big On BOT/BAL As Cash Burn And Catalysts Collide - Seeking Alpha
- 2 months ago - Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025 - Business Wire